Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

In recent decades, lung cancer treatment has been transformed—new surgeries, new radiation techniques, and dramatically ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other ...

Novocure (NASDAQ: NVCR) announced today that Japan’s Ministry of Health, Labour and Welfare approved reimbursement for Optune Lua® through the country’s National Health Insurance coverage.

February 2026 coverage highlighted combination EGFR therapy guidance, chemo-free treatment options, biomarker testing and ...

The past 30 years have seen tremendous progress in our fundamental understanding of lung cancer and the development of new treatment strategies,” senior researcher Dr. Cary Gross, a professor at Yale ...

Ohio University researchers have discovered what may be a new way to fight lung cancer that is resistant to other treatments.

Jiahui International Cancer Center (JICC) has stabilized a U.S. patient with advanced non‑small cell lung cancer (NSCLC) and ...

Explore new strategies for treating resistant lung cancer. Discover how blocking growth hormone receptors may improve ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

Researchers at Ohio University have discovered what may be a new way to fight lung cancer that is resistant to other treatments.